These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30968855)

  • 1. [Role of 18F-FDG PET/CT in comparison with CECT for whole-body assessment of patients with esophageal cancer.].
    Altini C; Niccoli Asabella A; Lavelli V; Bianco G; Ungaro A; Pisani A; Merenda N; Ferrari C; Rubini G
    Recenti Prog Med; 2019 Mar; 110(3):144-150. PubMed ID: 30968855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography.
    Altini C; Niccoli Asabella A; Di Palo A; Fanelli M; Ferrari C; Moschetta M; Rubini G
    Medicine (Baltimore); 2015 May; 94(20):e864. PubMed ID: 25997066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does [18F] fluorodeoxyglucose-positron emission tomography/computed tomography have a role in cervical nodal staging for esophageal squamous cell carcinoma?
    Li B; Li N; Liu S; Li Y; Qian B; Zhang Y; He H; Chen X; Sun Y; Xiang J; Hu H; Chen H
    J Thorac Cardiovasc Surg; 2020 Aug; 160(2):544-550. PubMed ID: 31932053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorodeoxyglucose-positron emission tomography/computed tomography performs better than contrast-enhanced computed tomography for metastasis evaluation in the initial staging of pancreatic adenocarcinoma.
    Santhosh S; Mittal BR; Bhasin DK; Rana SS; Gupta R; Das A; Nada R
    Ann Nucl Med; 2017 Oct; 31(8):575-581. PubMed ID: 28689356
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Mantziari S; Pomoni A; Prior JO; Winiker M; Allemann P; Demartines N; Schäfer M
    BMC Med Imaging; 2020 Jan; 20(1):7. PubMed ID: 31969127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Comparison of Computed Tomography Perfusion, Contrast-Enhanced Computed Tomography and Positron-Emission Tomography/Computed Tomography for the Detection of Primary Esophageal Carcinoma.
    Genc B; Kantarci M; Sade R; Orsal E; Ogul H; Okur A; Aydin Y; Karaca L; Eroğlu A
    Med Princ Pract; 2016; 25(3):254-9. PubMed ID: 26784024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer.
    Okada M; Murakami T; Kumano S; Kuwabara M; Shimono T; Hosono M; Shiozaki H
    Ann Nucl Med; 2009 Jan; 23(1):73-80. PubMed ID: 19205841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of (18)F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer.
    Altini C; Niccoli Asabella A; De Luca R; Fanelli M; Caliandro C; Quartuccio N; Rubini D; Cistaro A; Montemurro S; Rubini G
    Abdom Imaging; 2015 Jun; 40(5):1190-202. PubMed ID: 25348731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic values of mid-radiotherapy
    Kim N; Cho H; Yun M; Park KR; Lee CG
    Radiat Oncol; 2019 Feb; 14(1):27. PubMed ID: 30717809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective study comparing contrast-enhanced computed tomography with 18F-FDG-PET/CT in the early follow-up of patients with retroperitoneal sarcomas.
    Niccoli-Asabella A; Altini C; Notaristefano A; Merenda N; Altieri ML; Stabile-Ianora AA; Fanelli M; Rubini G
    Nucl Med Commun; 2013 Jan; 34(1):32-9. PubMed ID: 23111380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience.
    Cistaro A; Niccoli Asabella A; Coppolino P; Quartuccio N; Altini C; Cucinotta M; Alongi P; Balma M; Sanfilippo S; Buschiazzo A; Piccardo A; Fanelli M; Sambuceti G; Bomanji J; Baldari S; Bisi G; Fanti S; Rubini G
    Hell J Nucl Med; 2015; 18(2):97-102. PubMed ID: 26187207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Texture analysis of
    Nakajo M; Jinguji M; Nakabeppu Y; Nakajo M; Higashi R; Fukukura Y; Sasaki K; Uchikado Y; Natsugoe S; Yoshiura T
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):206-214. PubMed ID: 27613542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective validation of the role of PET/CT in detecting disease after neoadjuvant chemotherapy in advanced ovarian cancer.
    Lee EYP; Ip PPC; Tse KY; Chiu KWH; Chu MMY; Chai YK; Wu PY; Law JYP; Kwok ST; Chiu WK; Ngan HYS
    Eur Radiol; 2024 Sep; 34(9):5911-5922. PubMed ID: 38460014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole Body MRI in the Staging of Esophageal Cancer--A Prospective Comparison with Whole Body 18F-FDG PET-CT.
    Malik V; Harmon M; Johnston C; Fagan AJ; Claxton Z; Ravi N; O'Toole D; Muldoon C; Keogan M; Reynolds JV; Meaney JF
    Dig Surg; 2015; 32(5):397-408. PubMed ID: 26315570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
    Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF
    J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.
    Stiekema J; Vermeulen D; Vegt E; Voncken FE; Aleman BM; Sanders J; Boot H; van Sandick JW
    Clin Nucl Med; 2014 Oct; 39(10):862-7. PubMed ID: 25140549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and staging of cardiac masses: additional value of CMR with
    Mikail N; Males L; Hyafil F; Benali K; Deschamps L; Brochet E; Ehmer C; Driss AB; Saker L; Rossi A; Alkhoder S; Raffoul R; Rouzet F; Ou P
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2232-2241. PubMed ID: 35247063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis.
    Kroese TE; Goense L; van Hillegersberg R; de Keizer B; Mook S; Ruurda JP; van Rossum PSN
    Dis Esophagus; 2018 Dec; 31(12):. PubMed ID: 29917073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.